In silico-guided target identification of a scaffold-focused library: 1,3,5-Triazepan-2,6-diones as novel phospholipase A2 inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 23, 2006, Pages 6768-6778

  Muller, Pascal ^a   Lena, Gersande ^b   Boilard, Eric ^c   Bezzine, Sofiane ^c,d   Lambeau, Gérard ^c   Guichard, Gilles ^b   Rognan, Didier ^a  

^a CNRS   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d UNIVERSITY OF SFAX   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,5 TRIAZEPAN 2,6 ONE DERIVATIVE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL MEMBRANE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; DRUG BINDING; DRUG TARGETING; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; ESCHERICHIA COLI; HIGH THROUGHPUT SCREENING; HUMAN; ISOTOPE LABELING; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS;

AZEPINES; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, FACTUAL; DATABASES, PROTEIN; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; MODELS, MOLECULAR; PHOSPHOLIPASES A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750712502     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0606589     Document Type: Article

References (61)

1. Lindsay, M. A. Target discovery. Nat. Rev. Drug Discovery 2003, 2, 831-838.
2. Bleicher, K. H.; Bohm, H. J.; Muller, K.; Alanine, A. I. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discovery 2003, 2, 369-378.
3. Eggert, U. S.; Kiger, A. A.; Richter, C.; Perlman, Z. E.; Perrimon, N.; Mitchison, T. J.; Field, C. M. Parallel Chemical Genetic and Genome-Wide RNAi Screens Identify Cytokinesis Inhibitors and Targets. PLoS Biol. 2004, 2, e379.
4. Edwards, B. S.; Oprea, T.; Prossnitz, E. R.; Sklar, L. A. Flow cytometry for high-throughput, high-content screening. Curr. Opin. Chem. Biol. 2004, 8, 392-398.
5. Kwok, T. C.; Ricker, N.; Fraser, R.; Chan, A. W.; Burns, A.; Stanley, E. F.; McCourt, P.; Cutler, S. R.; Roy, P. A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature 2006, 441, 91-95.
6. Kubinyi, H. Chance favors the prepared mind-from serendipity to rational drug design. J. Recept. Signal Transduct. Res. 1999, 19, 15-39.
7. Hoffman, B. T.; Nelson, M. R.; Burdick, K.; Baxter, S. M. Protein tyrosine phosphatases: strategies for distinguishing proteins in a family containing multiple drug targets and anti-targets. Curr. Pharm. Des. 2004, 10, 1161-1181.
8. Leach, A. R.; Hann, M. M. The in silico world of virtual libraries. Drug Discovery Today 2000, 5, 326-336.
9. Parsons, A. B.; Geyer, R.; Hughes, T. R.; Boone, C. Yeast genomics and proteomics in drug discovery and target validation. Prog. Cell Cycle Res. 2003, 5, 159-166.
10. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discovery 2002, 1, 727-730.
11. Kauvar, L. M.; Higgins, D. L.; Villar, H. O.; Sportsman, J. R.; Engqvist-Goldstein, A.; Bukar, R.; Bauer, K. E.; Dilley, H.; Rocke, D. M. Predicting ligand binding to proteins by affinity fingerprinting. Chem. Biol. 1995, 2, 107-118.
12. Dixon, S. L.; Villar, H. O. Bioactive diversity and screening library selection via affinity fingerprinting. J. Chem. Inf. Comput. Sci. 1998, 38, 1192-1203.
13. Lessei, U. F.; Briem, H. Flexsim-X: a method for the detection of molecules with similar biological activity. J. Chem. Inf. Comput. Sci. 2000, 40, 246-253.
14. Bock, J. R.; Gough, D. A. Virtual screen for ligands of orphan G protein-coupled receptors. J. Chem. Inf. Model. 2005, 45, 1402-1414.
15. Oloff, S.; Zhang, S.; Sukumar, N.; Breneman, C.; Tropsha, A. Chemometric Analysis of Ligand Receptor Complementarity: Identifying Complementary Ligands Based on Receptor Information (CoLiBRI). J. Chem. Inf. Model. 2006, 46, 844-851.
16. Lamb, M. L.; Burdick, K. W.; Toba, S.; Young, M. M.; Skillman, A. G.; Zou, X.; Arnold, J. R.; Kuntz, I. D. Design, docking, and evaluation of multiple libraries against multiple targets. Proteins 2001, 42, 296-318.
17. Fernandes, M. X.; Kairys, V.; Gilson, M. K. Comparing ligand interactions with multiple receptors via serial docking. J. Chem. Inf. Comput. Sci. 2004, 44, 1961-1970.
18. Chen, Y. Z.; Ung, C. Y. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. J. Mol. Graph. Model. 2001, 20, 199-218.
19. Chen, Y. Z.; Zhi, D. G. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001, 43, 217-226.
20. Paul, N.; Kellenberger, E.; Bret, G.; Muller, P.; Rognan, D. Recovering the true targets of specific ligands by virtual screening of the protein data bank. Proteins 2004, 54, 671-680.
21. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
22. Hendlich, M.; Rippmann, F.; Barnickel, G. LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. J. Mol. Graph. Model. 1997, 15, 359-363, 389.
23. An, J.; Totrov, M.; Abagyan, R. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol. Cell. Proteomics 2005, 4, 752-761.
24. Kellenberger, E.; Muller, P.; Schalon, C.; Bret, G.; Foata, N.; Rognan, D. sc-PDB: an Annotated Database of Druggable Binding Sites from the Protein Data Bank. J. Chem. Inf. Model. 2006, 46, 717-727.
25. Gold, N. D.; Jackson, R. M. A searchable database for comparing protein-ligand binding sites for the analysis of structure-function relationships. J. Chem. Inf. Model. 2006, 46, 736-742.
26. Hu, L.; Benson, M. L.; Smith, R. D.; Lerner, M. G.; Carlson, H. A. Binding MOAD (Mother Of All Databases). Proteins 2005, 60, 333-340.
27. Schmitt, S.; Kuhn, D.; Klebe, G. A new method to detect related function among proteins independent of sequence and fold homology. J. Mol. Biol. 2002, 323, 387-406.
28. Gold, N. D.; Jackson, R. M. SitesBase: a database for structure-based protein-ligand binding site comparisons. Nucleic Acids Res. 2006, 34, D231-234.
29. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
30. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004, 57, 225-242.
31. The sc-PDB database is available at http://bioinfo-pharma.u-strasbg.fr/ sc-PDB.
32. Lena, G.; Lallemand, E.; Gruner, A. C.; Boeglin, J.; Roussel, S.; Schaffner, A. P.; Aubry, A.; Franetich, J. F.; Mazier, D.; Landau, I.; Briand, J. P.; Didierjean, C.; Rénia, L.; Guichard, G. 1,3,5-Triazepan-2,6-diones as Structurally Diverse and Conformationally Constrained Dipeptide Mimetics. Identification of Malaria Liver Stage Inhibitors From a Small Pilot Library. Chem. Eur. J. 2006, DOI: 10.1002/ chem.200600560.
33. We use a nomenclature based on the amino acid three letter code to describe 1,3,5-triazepan-2,6-diones. Accordingly, heterocycles prepared from the dipeptide sequence Boc-Xaa-Xbb-OH will be denoted cyclo(Xaa-gXbb-CO). g = gem, refers to the 2-alkyl gem-diamino-derivative of the corresponding amino acid according to the nomenclature proposed by Goodman et al. (Acc. Chem. Res. 1993, 26, 266-273).
34. Rodriguez, M.; Llinares, M.; Doulut, S.; Heitz, A.; Martinez, J. A facile synthesis of chiral N-protected β-amino alcohols. Tetrahedron Lett. 1991, 32, 923-926.
35. Sieber, P. A new acid-labile anchor group for the solid-phase synthesis of C-terminal peptide amides by the Fmoc method. Tetrahedron Lett. 1987, 28, 2107-2110.
36. Pan, Y. H.; Yu, B. Z.; Singer, A. G.; Ghomashchi, F.; Lambeau, G.; Gelb, M. H.; Jain, M. K.; Bahnson, B. J. Crystal structure of human group X secreted phospholipase A2. Electrostatically neutral interfacial surface targets zwitterionic membranes. J. Biol. Chem. 2002, 277, 29086-29093.
37. Jain, M. K.; Yu, B. Z.; Rogers, J.: Ranadive, G. N.; Berg, O. G. Interfacial catalysis by phospholipase A2: dissociation constants for calcium, substrate, products, and competitive inhibitors. Biochemistry 1991, 30, 7306-7317.
38. Volwerk, J. J.; Pieterson, W. A.; de Haas, G. H. Histidine at the active site of phospholipase A2. Biochemistry 1974, 13, 1446-1454.
39. Ancian, P.; Lambeau, G.; Lazdunski, M. Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2. Biochemistry 1995, 34, 13146-13151.
40. Schevitz, R. W.; Bach, N. J.; Carlson, D. G.; Chirgadze, N. Y.; Clawson, D. K.; Dillard, S. E.; Draheim, L. W.; Hartley, N. D.; Jones, E. D.; Mihelich, J. L.; Olkowski, D. W.; Snyder, C.; Sommers; Wery, J.-P. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nature Struct. Biol. 1995, 2, 458-465.
41. Smart, B. P.; Pan, Y. H.; Weeks, A. K.; Bollinger, J. G.; Bahnson, B. J. et al. Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structure-guided study. Bioorg. Med. Chem. 2004, 12, 1737-1749.
42. Dillard, R. D.; Bach, N. J.; Draheim, S. E.; Berry, D. R.; Carlson, D. G.; Chirgadze, N. Y.; Clawson, D. K.; Hartley, L. W.; Johnson, L. M.; Jones, N. D.; McKinney, E. R.; Mihelich, E. D.; Olkowski, J. L.; Schevitz, R. W.; Smith, A. C.; Snyder, D. W.: Sommers, C. D.; Wery, J. P. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides. J. Med. Chem. 1996, 39, 5119-5136.
43. Draheim, S. E.; Bach, N. J.; Dillard, R. D.; Berry, D. R.; Carlson, D. G.; Chirgadze, N. Y.; Clawson, D. K.; Hartley, L. W.; Johnson, L. M.; Jones, N. D.; McKinney, E. R.; Mihelich, E. D.; Olkowski, J. L.; Schevitz, R. W.; Smith, A. C.; Snyder, D. W.; Sommers, C. D.; Wery, J. P. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. J. Med. Chem. 1996, 39, 5159-5175.
44. Dillard, R. D.; Bach, N. J.; Draheim, S. E.; Berry, D. R.; Carlson, D. G.; Chirgadze, N. Y.; Clawson, D. K.; Hartley, L. W.; Johnson, L. M.; Jones, N. D.; McKinney, E. R.; Mihelich, E. D.; Olkowski, J. L.; Schevitz, R. W.; Smith, A. C.; Snyder, D. W.; Sommers, C. D.; Wery, J. P. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality. J. Med. Chem. 1996, 39, 5137-5158.
45. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L., 3rd Assessing scoring functions for protein-ligand interactions. J. Med. Chem. 2004, 47, 3032-3047.
46. Deng, Z.; Chuaqui, C.; Singh, J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J. Med. Chem. 2004, 47, 337-344.
47. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
48. Pieper, U.; Eswar, N.; Davis, F. P.; Braberg, H.; Madhusudhan, M. S.; Rossi, A.; Marti-Renom, M.; Karchin, R.; Webb, B. M.; Eramian, D.; Shen, M. Y.; Kelly, L.; Melo, F.; Sali, A. MODBASE: a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res. 2006, 34, D291-295.
49. Scott, K. F.; Graham, G. G.; Bryant, K. J. Secreted phospholipase A2 enzymes as therapeutic targets. Expert Opin. Ther. Targets 2003, 7, 427-440.
50. Laye, J. P.; Gill, J. H. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discovery Today 2003, 8, 710-716.
51. Reid, R. C. Inhibitors of secretory phospholipase A2 group IIA. Curr. Med. Chem. 2005, 12, 3011-3026.
52. Webb, N. R. Secretory phospholipase A2 enzymes in atherogenesis. Curr. Opin. Lipidot. 2005, 16, 341-344.
53. Triggiani, M.; Granata, F.; Giannattasio, G.; Marone, G. Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J. Allergy Clin. Immunol. 2005, 116, 1000-1006.
54. Meyer, M. C.; Rastogi, P.; Beckett, C. S.; McHowat, J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr. Pharm. Des. 2005, 11, 1301-1312.
55. Singer, A. G.; Ghomashchi, F.; Le Calvez, C.; Bollinger, J.; Bezzine, S.; Rouault, M.; Sadilek, M.; Nguyen, E.; Lazdunski, M.; Lambeau, G.; Gelb, M. H. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J. Biol. Chem. 2002, 277, 48535-48549.
56. Smart, B. P.; Oslund, R. C.; Walsh, L. A.; Gelb, M. H. The first potent inhibitor of Mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. J. Med. Chem. 2006, 49, 2858-2860.
57. Murakami, M. Hot topics in phospholipase A2 field. Biol. Pharm. Bull. 2004, 27, 1179-1182.
58. Murakami, M.; Kudo, I. Secretory phospholipase A2. Biol. Pharm. Bull. 2004, 27, 1158-1164.
59. Jones, G.; Wilett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
60. SYBYL 6.91, Tripos Assoc., Inc.: St. Louis, MO.
61. Bairoch, A. The ENZYME database in 2000. Nucleic Acids Res 2000, 28, 304-305.